Contineum Therapeutics (CTNM) Morgan Stanley 22nd Annual Global Healthcare Conference summary

Company and pipeline overview

• Focuses on neuroscience, inflammation, and immunology, targeting high unmet medical needs with de-risked assets before clinical phases.

• Two clinical-stage assets: PIPE-791 (LPA1 inhibitor) for progressive MS and idiopathic pulmonary fibrosis (IPF), and PIPE-307 (M1 receptor antagonist) for remyelination and depression.

• All assets are internally derived, with no external licenses.

• PIPE-307 partnered with J&J for phase II studies in relapsing-remitting MS and depression.

• Clinical validation supports programs in three of four targeted diseases.

PIPE-791: LPA1 inhibitor for IPF and MS

• Completed healthy volunteer study in H1 2024; PET study to start by year-end, with data expected early 2025.

• IPF has 130,000–140,000 US patients; current therapies have poor adoption due to side effects and high discontinuation rates.

• PIPE-791 aims for once-daily dosing, improved safety, and best-in-class receptor occupancy, differentiating from competitors requiring BID dosing.

• Phase II proof-of-concept in IPF planned for mid-2025, with phase III as the base case for registration.

• No food effect observed in dosing; convenient regimen seen as key for elderly IPF patients.

PIPE-307: M1 receptor antagonist for MS and depression

• Inspired by clinical validation from clemastine studies showing remyelination in MS.

• Selective M1 antagonism avoids cognitive side effects seen with broad antimuscarinics.

• Phase II VISTA study in relapsing-remitting MS started late 2023, with 168 patients across three cohorts; primary endpoints are safety, tolerability, and remyelination via low contrast letter acuity.

• Secondary endpoints include MRI measures and neurofilament light.

• J&J to initiate depression study with PIPE-307 by year-end.